Digistain

Digistain operates in the biotechnology and healthtech sector, specialising in cancer diagnostics and breast cancer risk profiling. The company has developed an AI-enabled biomarker analytics platform that supports faster, lower-cost assessment of hormone receptor-positive breast cancer. Its services help clinicians analyse tissue samples, generate prognostic scores and assess the likelihood of cancer recurrence, supporting treatment decisions such as whether chemotherapy may be required alongside hormone therapy. Digistain’s work combines digital pathology, biomedical optics and clinical research, aiming to improve the speed, accessibility and consistency of cancer grading and prognosis for healthcare providers and patients.